Inolimomab

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameInolimomab
Drug Alias NameAnti-interleukin-2 receptor monoclonal antibody B-B10伊诺利莫单抗Inolimomabum伊诺莫单抗Anti-CD25 monoclonal antibody B-B10 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEusa PharmaJazz Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElsalys Biotech
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksWikipedia